Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Blood Année : 2014

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

Zahir Amoura
  • Fonction : Auteur
  • PersonId : 941145

Résumé

Erdheim-Chester disease (ECD) is a rare histiocytic disorder that is challenging to diagnose and treat. We performed molecular analysis of BRAF in the largest cohort of ECD patients studied to date followed by N/KRAS, PIK3CA, and AKT1 mutational analysis in BRAF wild-type patients. Forty-six of 80 (57.5%) of patients were BRAFV600E-mutant. NRAS mutations were detected in 3 of 17 ECD BRAFV600E wild-type patients. PIK3CA mutations (p.E542K, p.E545K, p.A1046T, and p.H1047R) were detected in 7 of 55 patients, 4 of whom also had BRAF mutations. Mutant NRAS was present in peripheral blood CD14(+) cells, but not lymphoid cells, from an NRASQ61R mutant patient. Our results underscore the central role of RAS-RAF-MEK-ERK activation in ECD and identify an important role of activation of RAS-PI3K-AKT signaling in ECD. These results provide a rationale for targeting mutant RAS or PI3K/AKT/mTOR signaling in the subset of ECD patients with NRAS or PIK3CA mutations.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02299579 , version 1 (27-09-2019)

Identifiants

Citer

J.-F. Emile, E. Diamond, Z. Helias-Rodzewicz, F. Cohen-Aubart, F. Charlotte, et al.. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124 (19), pp.3016-3019. ⟨10.1182/blood-2014-04-570937⟩. ⟨inserm-02299579⟩
62 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More